Amneal Pharmaceuticals, Inc Class A Common Stock

Yahoo Finance • 3 days ago

The Bull Case For Amneal Pharmaceuticals (AMRX) Could Change Following Biosimilar XOLAIR FDA Submission – Learn Why

Amneal Pharmaceuticals recently announced the submission of a Biologics License Application to the U.S. FDA for a proposed biosimilar to XOLAIR®, a leading therapy with approximately US$4.1 billion in annual U.S. sales, and will present at... Full story

Yahoo Finance • 11 days ago

Amneal Pharmaceuticals, Inc. (AMRX) Files BLA for XOLAIR® Biosimilar, Targets Multi-Billion-Dollar Market

We recently compiled a list of the 12 Healthcare Stocks with Insider Buying in 2025. Amneal Pharmaceuticals, Inc. is one of them. Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) continues to strengthen its position in generic, branded, and spe... Full story

Yahoo Finance • 12 days ago

Amneal to Report Third Quarter 2025 Results on October 30, 2025

BRIDGEWATER, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced that the Company will release its third quarter 2025 finan... Full story

Yahoo Finance • 16 days ago

Amneal seeks FDA nod for generic targeting Xolair marketed by Roche and Novartis

[US Food and Drug Administration (FDA)] * Amneal Pharmaceuticals (NASDAQ:AMRX [https://seekingalpha.com/symbol/AMRX]) on Friday announced the FDA submissions to seek U.S. approval for an off-patent version of Xolair, an asthma therapy m... Full story

Yahoo Finance • 16 days ago

Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab)

BRIDGEWATER, N.J., Sept. 26, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administratio... Full story

Yahoo Finance • 19 days ago

Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%

Amneal Pharmaceuticals LLC Important ophthalmic treatment for patients and expected to be a key growth driver for Amneal’s Affordable Medicines segment BRIDGEWATER, N.J., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“... Full story

Yahoo Finance • last month

Amneal wins FDA nod for generic targeting Jazz Pharma’s Xyrem

[FDA Seal of Approval and Rubber Stamp] asbe/iStock via Getty Images Amneal Pharmaceuticals (NASDAQ:AMRX [https://seekingalpha.com/symbol/AMRX]) announced on Thursday that the U.S. Food and Drug Administration (FDA) approved its generic p... Full story

Yahoo Finance • last month

Amneal gets FDA nod for generic version of Risperdal Consta

[Anatomical 3D illustration of the transparent human head interior.] AntonioGuillem/iStock via Getty Images * Amneal Pharmaceuticals (NASDAQ:AMRX [https://seekingalpha.com/symbol/AMRX]) has received approval from the U.S. FDA for its an... Full story

Yahoo Finance • last month

Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension

Another addition to Amneal’s growing complex injectables portfolio reflects leadership in advanced development and manufacturing of complex pharmaceuticals BRIDGEWATER, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, In... Full story

Yahoo Finance • 2 months ago

Amneal raises 2025 guidance and targets $300M–$500M peak CREXONT sales as new launches accelerate

Earnings Call Insights: Amneal Pharmaceuticals (AMRX) Q2 2025 MANAGEMENT VIEW * Chirag K. Patel, Co-Founder and Co-CEO, highlighted "another consecutive quarter of strong performance and growth with revenues of $720 million and adjuste... Full story

Yahoo Finance • 2 months ago

Knight Therapeutics Announces Regulatory Submission of CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Mexico

MONTREAL, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.... Full story

Yahoo Finance • 2 months ago

Thérapeutique Knight annonce la soumission réglementaire au Mexique de CREXONT® (carbidopa et lévodopa) en capsules à libération prolongée

MONTRÉAL, 05 août 2025 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD) (« Knight »), société pharmaceutique spécialisée panaméricaine (hors États-Unis), a annoncé aujourd’hui que sa filiale mexicaine, Grupo Biotoscana de Especi... Full story

Yahoo Finance • 2 months ago

Amneal Pharmaceuticals Inc (NASDAQ:AMRX) Reports Mixed Q2 2025 Results: Earnings Beat, Revenue Miss

Amneal Pharmaceuticals Inc (NASDAQ:AMRX [https://www.chartmill.com/stock/quote/AMRX/profile]) reported mixed second-quarter 2025 results, with earnings surpassing expectations while revenue fell short. The market reaction has been cautious... Full story

Yahoo Finance • 2 months ago

Amneal Reports Second Quarter 2025 Financial Results

‒ Q2 2025 Net Revenue of $725 million; GAAP Net Income of $22 million; Diluted Income per Share of $0.07 ‒ ‒ Adjusted EBITDA of $184 million; Adjusted Diluted EPS of $0.25 ‒ ‒ Raising 2025 Full Year Guidance ‒ ‒ Full Debt Refinancing Reduc... Full story

Yahoo Finance • 2 months ago

Here are the major earnings before the open Tuesday

Major earnings expected before the bell on Tuesday include: * Pfizer (PFE [https://seekingalpha.com/symbol/PFE]) * Caterpillar (CAT [https://seekingalpha.com/symbol/CAT]) * BP p.l.c. (BP [https://seekingalpha.com/symbol/BP]) * Org... Full story

Yahoo Finance • 3 months ago

Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032

BRIDGEWATER, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal”) (Nasdaq: AMRX) announced that its subsidiary, Amneal Pharmaceuticals LLC (the “Issuer”), is seeking to borrow $1.800 billion aggregate principal... Full story

Yahoo Finance • 3 months ago

Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results

– Results Reflect Continued Financial Strength and Deleveraging – BRIDGEWATER, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced certain unaudited preliminary... Full story

Yahoo Finance • 3 months ago

Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Canada

MONTREAL, July 18, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that Knight's New Drug Submission (NDS) for CREXONT® has been accepted... Full story

Yahoo Finance • 3 months ago

Thérapeutique Knight annonce le dépôt d’une nouvelle soumission réglementaire pour CREXONT® (carbidopa et lévodopa) au Canada en capsules à libération prolongée

MONTRÉAL, 18 juill. 2025 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD) (« Knight »), société pharmaceutique spécialisée panaméricaine (hors États-Unis), a annoncé aujourd’hui que la soumission de drogue nouvelle (SDN) pour CR... Full story

Yahoo Finance • 3 months ago

Amneal Pharmaceuticals (AMRX) Announces FDA Approval of Prednisolone Acetate Ophthalmic Suspension

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is one of the 13 Best Healthcare Stocks to Buy Under $10. On June 12, Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) announced the FDA approval of prednisolone acetate ophthalmic suspension, with laun... Full story